| Ipatasertib studied in …STUDIED_INderived50 of 50show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 50 trials list this drug (21 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05564377Phase 2 · recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial · 50 trials list this drug (21 active) | — | — | Malignant Solid Neoplasm,Primary Peritoneal Carcinoma,Malignant Female Reproductive System Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05172245Phase 1 · recruiting Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer · 50 trials list this drug (21 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Malignant Sinonasal Neoplasm,Head and Neck Carcinoma of Unknown Primary+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05276973Phase 1 · active not recruiting Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer · 50 trials list this drug (21 active) | — | — | Fallopian Tube Endometrioid Adenocarcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05172258Phase 2 · active not recruiting Testing the Addition of an Anti-cancer Drug, Ipatasertib, to the Usual Immunotherapy Treatment (Pembrolizumab) in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck · 50 trials list this drug (21 active) | — | — | Malignant Lip and Oral Cavity Neoplasm,Head and Neck Squamous Cell Carcinoma,Malignant Laryngeal Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03424005Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 50 trials list this drug (21 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04589845Phase 2 · active not recruiting Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study · 50 trials list this drug (21 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04802759Phase 1/Phase 2 · recruiting A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer · 50 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05862285Phase 3 · recruiting A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study · 50 trials list this drug (21 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05554380Phase 2 · active not recruiting Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial · 50 trials list this drug (21 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959891Phase 1 · active not recruiting AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC) · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05538897Phase 1/Phase 2 · active not recruiting Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers · 50 trials list this drug (21 active) | — | — | Endometrial Endometrioid Adenocarcinoma,FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma,FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06400251Phase 2 · active not recruiting Testing Ipatasertib as Potentially Targeted Treatment in Cancers With AKT Genetic Changes (MATCH - Subprotocol Z1K) · 50 trials list this drug (21 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03337698Phase 1/Phase 2 · terminated A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) · 50 trials list this drug (21 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05498896Phase 2 · active not recruiting Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC · 50 trials list this drug (21 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04920708Phase 2 · active not recruiting Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression · 50 trials list this drug (21 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04650581Phase 3 · active not recruiting Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04486352Phase 1/Phase 2 · recruiting A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer · 50 trials list this drug (21 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04253561Phase 1 · completed Ipatasertib + Pertuzumab +Trastuzumab in Advanced HER2+ PI3KCA-mutant Breast Cancer Patients · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 50 trials list this drug (21 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03280563Phase 1/Phase 2 · completed A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer · 50 trials list this drug (21 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03385655Phase 2 · active not recruiting Prostate Cancer Biomarker Enrichment and Treatment Selection · 50 trials list this drug (21 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03072238Phase 3 · completed Ipatasertib Plus Abiraterone Plus Prednisone/Prednisolone, Relative to Placebo Plus Abiraterone Plus Prednisone/Prednisolone in Adult Male Patients With Metastatic Castrate-Resistant Prostate Cancer · 50 trials list this drug (21 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03673787Phase 1/Phase 2 · active not recruiting A Trial of Ipatasertib in Combination With Atezolizumab · 50 trials list this drug (21 active) | — | — | Solid Neoplasm,Glioblastoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05332561Phase 2 · recruiting Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE) · 50 trials list this drug (21 active) | — | — | Early Stage Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551521Phase 2 · completed CRAFT: The NCT-PMO-1602 Phase II Trial · 50 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04632992Phase 2 · completed A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response · 50 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04060862Phase 1 · terminated A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03800836Phase 1 · completed A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464174Phase 2 · completed Ipatasertib Plus Non-Taxane Chemotherapy for Advanced or Metastatic Triple-Negative Breast Cancer · 50 trials list this drug (21 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03395899Phase 2 · completed Pre-operative Immunotherapy Combination Strategies in Breast Cancer · 50 trials list this drug (21 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04177108Phase 3 · completed A Study of Ipatasertib in Combination With Atezolizumab and Paclitaxel as a Treatment for Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer · 50 trials list this drug (21 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03337724Phase 3 · completed A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03853707Phase 1/Phase 2 · completed Ipatasertib in Combination With Carboplatin, Carboplatin/Paclitaxel, or Capecitabine/Atezolizumab in Treating Patients With Metastatic Triple Negative Breast Cancer · 50 trials list this drug (21 active) | — | — | Triple-Negative Breast Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04737109Phase 1/Phase 2 · terminated Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer · 50 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04467801Phase 2 · unknown Ipatasertib and Docetaxel in Metastatic NSCLC Patients Who Have Failed 1st Line Immunotherapy · 50 trials list this drug (21 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03840200Phase 1 · completed A Study Evaluating the Safety, Pharmacokinetics and Efficacy of Ipatasertib Administered in Combination With Rucaparib in Participants With Advanced Breast, Ovarian Cancer, and Prostate Cancer. · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm,Malignant Ovarian Neoplasm,Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404140Phase 1 · terminated A Study Evaluating The Safety, Efficacy and Pharmacokinetics Of Ipatasertib In Combination With Atezolizumab And Docetaxel In Metastatic Castration-Resistant Prostate Cancer (mCRPC). · 50 trials list this drug (21 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01485861Phase 1/Phase 2 · completed Study of Ipatasertib or Apitolisib With Abiraterone Acetate Versus Abiraterone Acetate in Participants With Castration-Resistant Prostate Cancer Previously Treated With Docetaxel Chemotherapy · 50 trials list this drug (21 active) | — | — | Malignant Prostate Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04341259Phase 1 · completed A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors. · 50 trials list this drug (21 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01896531Phase 2 · completed A Study of Ipatasertib (GDC-0068) in Combination With Fluoropyrimidine Plus Oxaliplatin in Participants With Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer · 50 trials list this drug (21 active) | — | — | Malignant Gastric Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01362374Phase 1 · completed Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors · 50 trials list this drug (21 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02162719Phase 2 · completed A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors · 50 trials list this drug (21 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04561817Phase 2 · withdrawn To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer · 50 trials list this drug (21 active) | — | — | Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02301988Phase 2 · completed A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Participants With Early Stage Triple Negative Breast Cancer · 50 trials list this drug (21 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02536391Phase 1 · completed Ipatasertib (GDC-0068) Study to Evaluate Formulation Change and Food Effect on Bioavailability in Healthy Subjects · 50 trials list this drug (21 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01090960Phase 1 · completed A Study Evaluating the Safety and Tolerability of GDC-0068 in Patients With Refractory Solid Tumors · 50 trials list this drug (21 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01562275Phase 1 · completed A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors · 50 trials list this drug (21 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |